Trebananib

Oncology

Takedaprotein_peptidePhase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

928 Active assets in the Oncology cohort.

Asset / Sponsor	Phase	Rating
PANITUMUMAB Astellas Pharma Inc	Phase 2	BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi	Phase 4	BB
Relatlimab Bristol-Myers Squibb	Phase 2	BB
DINITROGEN MONOXIDE Medical College of Wisconsin	Phase 4	BB
LIDOCAINE Medical College of Wisconsin	Phase 4	BB

View all 50 →

Same molecule, other indications

Trebananib is also rated in:

renal cell carcinomaDormant

BB

Indicative ·

67 / 100

primary peritoneal carcinomaDormant

BB

Indicative ·

64 / 100

hepatocellular carcinomaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.